1. Home
  2. CRNX vs RNST Comparison

CRNX vs RNST Comparison

Compare CRNX & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.97

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

RNST

Renasant Corporation

HOLD

Current Price

$41.20

Market Cap

4.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
RNST
Founded
2008
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.0B
IPO Year
2018
1997

Fundamental Metrics

Financial Performance
Metric
CRNX
RNST
Price
$84.97
$41.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$76.75
$43.00
AVG Volume (30 Days)
2.4M
514.7K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
2.31%
EPS Growth
N/A
N/A
EPS
N/A
1.88
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$31.72
Revenue Next Year
$184.67
$4.67
P/E Ratio
N/A
$21.62
Revenue Growth
N/A
N/A
52 Week Low
$32.30
$33.04
52 Week High
$85.01
$44.54

Technical Indicators

Market Signals
Indicator
CRNX
RNST
Relative Strength Index (RSI) 89.88 42.11
Support Level $83.47 $40.85
Resistance Level N/A $44.12
Average True Range (ATR) 0.12 0.96
MACD -0.86 -0.13
Stochastic Oscillator 93.85 43.31

Price Performance

Historical Comparison
CRNX
RNST

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

Share on Social Networks: